Search Results

Genelux Corporation (NASDAQ: GNLX) and TVAX Biomedical, Inc. today announced that the United States Patent and Trademark Office granted a patent claiming methods of combining vaccine-enhanced adoptive T cell therapy with oncolytic virus adjunct therapy.

As the Trump administration—including HHS Secretary Robert F. Kennedy Jr.—plays fast and loose with scientific studies and facts, there may be a more sinister force at play: censorship.

At Drexel University’s Graduate School of Biomedical Sciences and Professional Studies, graduate students and active professionals can take interdisciplinary, career-oriented programs designed to help launch their careers and take them to the next level.

TVAX Biomedical (TVAX), is a cancer immunotherapy company that is moving into its pivotal glioblastoma study for FDA regulatory approval. TVAX Immunotherapy® could fundamentally change the way cancer is treated as T cells can kill all cancer cells, including cancer stem cells, without the toxicity of current treatments. With early